Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2009-12-11

Clinical Trial Update: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Leuprolide (antigonadotropin) in Alzheimer's disease. The ALADDIN VP 104 study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lupron (leuprolide)

Snippet

Sponsor: Voyager Pharmaceutical Corporation | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED